Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors-Reference-Cited by-同舟云学术

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Published:2015-07 Issue:7 Volume:26 Page:1421-1427
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Kris M.G.,Camidge D.R.,Giaccone G.,Hida T.,Li B.T.,O'Connell J.,Taylor I.,Zhang H.,Arcila M.E.,Goldberg Z.,Jänne P.A.

Funder

Pfizer, Inc.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/7/1421/16702816/mdv186.pdf

Reference31 articles.

1. Lung cancer: intragenic ERBB2 kinase mutations in tumours;Stephens;Nature,2004

2. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas;Shigematsu;Cancer Res,2005

3. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas;Arcila;Clin Cancer Res,2012

4. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;JAMA,2014

5. Europe does it better: molecular testing across a national health care system-the French example;Nowak;Am Soc Clin Oncol Educ Book,2013

Cited by 260 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and biological evaluation of diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFRL858R/T790M/C797S inhibitors;European Journal of Medicinal Chemistry;2024-12

2. Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas;Cancers;2024-09-13

3. Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study;Discover Oncology;2024-07-16

4. SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study;Signal Transduction and Targeted Therapy;2024-07-15

5. Spotlight on the treatment of non‐small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives;International Journal of Cancer;2024-07-03